Profile of crizanlizumab and its potential in the prevention of pain crises in sickle cell disease: evidence to date

References

• Ashley-Koch A, Yang Q, Olney RS. Sickle hemoglobin (Hb S) Allele and Sickle cell disease: a HuGE review. Am J Epidemiol. 2000;151(9):839–845. doi:10.1093/oxfordjournals.aje.a01028810791557
   PubMed Web of Science ®Google Scholar
• Saraf SL, Molokie RE, Nouraie M, et al. Differences in the clinical and genotypic presentation of sickle cell disease around the world. Paediatr Respir Rev. 2014;15(1):4–12.24361300
   PubMed Web of Science ®Google Scholar
• Piel FB, Steinberg MH, Rees DC. Sickle cell disease. N Engl J Med. 2017;376(16):1561–1573. doi:10.1056/NEJMra151086528423290
   PubMed Web of Science ®Google Scholar
• Riley TR, Boss A, McClain D, Riley TT. Review of medication therapy for the prevention of sickle cell crisis. Pharm Ther. 2018;43(7):417–437.
   Google Scholar
• Okam MM, Shaykevich S, Ebert BL, Zaslavsky AM, Ayanian JZ. National trends in hospitalizations for sickle cell disease in the United States following the FDA approval of hydroxyurea, 1998-2008. Med Care. 2014;52(7):612–618. doi:10.1097/MLR.000000000000014324926708
   PubMed Web of Science ®Google Scholar
• Steiner CA, Miller JL. Sickle cell disease patients in U.S. hospitals, 2004. HCUP Statistical Brief #21. Agency for Healthcare Research and Quality; 12 2006 Available from: www.hcup-us.ahrq.gov/reports/statbriefs/sb21.pdf. Accessed 807, 2019.
   Google Scholar
• Serjeant GR. Sickle-cell disease. Lancet. 1997;350(9079):725–730. doi:10.1016/S0140-6736(97)07330-39291916
   PubMed Web of Science ®Google Scholar
• Stuart MJ, Nagel RL. Sickle cell disease. Lancet. 2004;364(9442):1343–1360. doi:10.1016/S0140-6736(04)17192-415474138
   PubMed Web of Science ®Google Scholar
• Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. Lancet. 2017;390(10091):311–323. doi:10.1016/S0140-6736(17)30193-928159390
   PubMed Web of Science ®Google Scholar
• Serjeant GR. The natural history of sickle cell disease. Cold Spring Harb Perspect Med. 2013;3(10):a011783. doi:10.1101/cshperspect.a01551123813607
   PubMed Web of Science ®Google Scholar
• Hebbel RP, Yamada O, Moldow CF, Jacob HS, White JG, Eaton JW. Abnormal adherence of sickle erythrocytes to cultured vascular endothelium: possible mechanism for microvascular occlusion in sickle cell disease. J Clin Invest. 1980;65(1):154–160. doi:10.1172/JCI1096467350195
   PubMed Web of Science ®Google Scholar
• Kaul DK, Finnegan E, Barabino GA. Sickle red cell-endothelium interactions. Microcirculation. 2009;16(1):97–111. doi:10.1080/1073968080227939418720225
   PubMed Web of Science ®Google Scholar
• Ataga KI, Kutlar A, Kanter J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017;376(5):429–439. doi:10.1056/NEJMoa161177027959701
   PubMed Web of Science ®Google Scholar
• Uwaezuoke SN, Ayuk AC, Ndu IK, Eneh CI, Mbanefo NR, Ezenwosu OU. Vaso-occlusive crisis in sickle cell disease: current paradigm on pain management. J Pain Res. 2018;11:3141–3150. doi:10.2147/JPR.S18558230588066
   PubMed Web of Science ®Google Scholar
• Manwani D, Frenette PS. Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies. Blood. 2013;122(24):3892–3898. doi:10.1182/blood-2013-05-49831124052549
   PubMed Web of Science ®Google Scholar
• Morris CR. Mechanisms of vasculopathy in sickle cell disease and thalassemia. Hematol Am Soc Hematol Educ Program. 2008;2008:177–185. doi:10.1182/asheducation-2008.1.177
   Google Scholar
• Gutsaeva DR, Parkerson JB, Yerigenahally SD, et al. Inhibition of cell adhesion by anti-P-selectin aptamer: a new potential therapeutic agent for sickle cell disease. Blood. 2011;117(2):727–735. doi:10.1182/blood-2010-05-28571820926770
   PubMed Web of Science ®Google Scholar
• Yu Z, Blankenship L, Jaiyesimi I. Crizanlizumab in sickle cell disease. N Engl J Med. 2017;376(18):1795–1796. doi:10.1056/NEJMc170316228467873
   PubMed Web of Science ®Google Scholar
• Heeney MM, Ware RE. Hydroxyurea for children with sickle cell disease. Pediatr Clin North Am. 2008;55(2):483–501, x. doi:10.1016/j.pcl.2008.02.00318381097
   PubMed Web of Science ®Google Scholar
• Brandow AM, Panepinto JA. Hydroxyurea use in sickle cell disease: the battle with low prescription rates, poor patient compliance and fears of toxicities. Expert Rev Hematol. 2010;3(3):255–260. doi:10.1586/ehm.10.2221082977
   PubMed Web of Science ®Google Scholar
• Siklos (hydroxyurea) [package insert]. Bryn Mawr, Pennsylvania: Medunik USA, Inc; 2017.
   Google Scholar
• Ataga KI, Kutlar A, Kanter J. Crizanlizumab in sickle cell disease. N Engl J Med. 2017;376(18):1795–1796. doi:10.1056/NEJMc170316228467873
   PubMed Web of Science ®Google Scholar
• Kutlar A, Kanter J, Liles DK, et al. Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: a SUSTAIN study analysis. Am J Hematol. 2019;94(1):55–61. doi:10.1002/ajh.2530830295335
   PubMed Web of Science ®Google Scholar
• Ware RE, Despotovic JM, Mortier NA, et al. Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. Blood. 2011;118(18):4985–4991. doi:10.1182/blood-2011-07-36419021876119
   PubMed Web of Science ®Google Scholar
• Sins JWR, Mager DJ, Davis SCAT, Biemond BJ, Fijnvandraat K. Pharmacotherapeutical strategies in the prevention of acute, vaso-occlusive pain in sickle cell disease: a systematic review. Blood Adv. 2017;1(19):1598–1616. doi:10.1182/bloodadvances.201700721129296801
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Study of dose confirmation and safety of crizanlizumab in pediatric sickle cell disease patients. NCT03474965. Available from: https://clinicaltrials.gov/ct2/show/NCT03474965. Accessed 612, 2019.
   Google Scholar
• ClinicalTrials.gov. Pharmacokinetics and pharmacodynamics study of SEG101 (Crizanlizumab) in sickle cell disease (SCD) patients with vaso- occlusive crisis (VOC). NCT03264989. Available from: https://clinicaltrials.gov/ct2/show/NCT03264989. Accessed 612, 2019.
   Google Scholar
• ClinicalTrials.gov. Study of two doses of crizanlizumab versus placebo in adolescent and adult sickle cell disease patients (STAND). NCT03814746. Available from: https://clinicaltrials.gov/ct2/show/NCT03814746. Accessed 612, 2019.
   Google Scholar
• ClinicalTrials.gov. A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism (SPARTAN). NCT03938454. Available from: https://clinicaltrials.gov/ct2/show/NCT03938454. Accessed 612, 2019.
   Google Scholar
• Novartis. Press release: Novartis investigational therapy crizanlizumab (SEG101) receives FDA breakthrough therapy designation for the prevention of vaso-occlusive crises in sickle cell disease. 1 8, 2019 Available from: https://www.novartis.com/news/media-releases/novartis-investigational-therapy-crizanlizumab-seg101-receives-fda-breakthrough-therapy-designation-prevention-vaso-occlusive-crises-sickle-cell-disease. Accessed 612, 2019.
   Google Scholar